The more extensive tissue sampling protocol is designed to detect clinically
occult cancer and hence it is a form of cancer screening with low-volume, low-grade, generally clinically insignificant cancer detected in about 5% of these specimens.
An additional concern with performing hysterectomy for definitive management of cervical dysplasia is the concern that
occult cancer may be missed preoperatively, and that the hysterectomy is inadequate surgical clearance of the disease.
Shivakumar et al., "Screening for
occult cancer in unprovoked venous thromboembolism," New England Journal of Medicine, vol.
The relationship between
occult cancer and venous thromboembolism (VTE) has been recognized for many years.
Patients with a blood test showing thrombocytosis should be screened for
occult cancer. This is the finding of research from Exeter, UK.
Thus, in patients diagnosed as having DVT, systematic medical workup is necessary to identify any
occult cancer. In cancer patients, death from DVT is second in frequency only to death from the tumor per se [7].
Occult cancer in women with dense breasts: detection with screening US--diagnostic yield and tumor characteristics.
The decision to pursue supplemental screening should be based on an informed discussion of the patient's individual breast density and cancer risk, as well as an understanding of the likelihood of detecting a mammographically
occult cancer versus false-positive findings that may lead to anxiety, follow-up Imaging, and biopsy.
It's reasonable to assume that the vast majority of cancers identified within a year following diagnosis of a venous leg ulcer were probably present at the time when the ulcer was first diagnosed, meaning venous leg ulcers can serve as a red flag for
occult cancer.
This approach leaves men at risk of
occult cancer, leading to a high rate of repeat biopsies, often on cancer-free men.
According to Galena Biopharma, the nelipepimut-S sequence stimulates specific CD8+ cytotoxic T lymphocytes (CTLs) after binding to HLA-A2/A3 molecules on antigen presenting cells and the activated specific CTLs recognise, neutralise and destroy, through cell lysis, HER2 expressing cancer cells, including
occult cancer cells and micrometastatic foci.
In addition to indicating the presence of an
occult cancer, the patterns of chromosomal aberrations, single-nucleotide mutations, and structural variants identified in plasma may also be useful to determine what type of cancer is present.
